Fuentes Elisa, Jairoce Chenjerai, Macià Didac, Mayer Leonie, Torres-Yaguana Jorge P, Vidal Marta, Santano Rebeca, Narum David L, Cavanagh David, Gamain Benoit, Coppel Ross L, Beeson James G, Dutta Sheetij, Sacarlal Jahit, Aguilar Ruth, Moncunill Gemma, Dobaño Carlota
ISGlobal, Barcelona, Spain.
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
NPJ Vaccines. 2025 Jun 6;10(1):116. doi: 10.1038/s41541-025-01167-0.
RTS,S/AS01 is the first malaria vaccine implemented for young African children. However, it provides partial protection against Plasmodium falciparum (Pf) malaria, and a better understanding of the mechanisms and determinants of vaccine immunity will help develop second-generation improved vaccines. We measured IgG to vaccine target and Pf blood-stage off-target proteins before and after vaccination in 874 children aged 1-4 years in a phase 2b trial of RTS,S/AS02 in Mozambique. We found that naturally acquired PfCSP IgG levels pre-vaccination were positively associated with RTS,S immunogenicity. Increased levels of IgG to the C-terminus and NANP-repeat regions of PfCSP, and to PfMSP5 and PfMSP1 block 2, following vaccination, were significantly associated with a lower hazard of clinical malaria over 6 months. Thus, immune priming, anti-PfCSP C-terminus and off-target antibody responses contributed to malaria protection after adjusting for prior Pf exposure, and this could guide strategies for optimizing the immunogen and vaccine deployment.
RTS,S/AS01是首个用于非洲幼儿的疟疾疫苗。然而,它对恶性疟原虫(Pf)疟疾仅提供部分保护,更好地理解疫苗免疫的机制和决定因素将有助于研发第二代改进型疫苗。在莫桑比克进行的RTS,S/AS02 2b期试验中,我们测量了874名1至4岁儿童接种疫苗前后针对疫苗靶点和Pf血期非靶点蛋白的IgG。我们发现,接种疫苗前自然获得的PfCSP IgG水平与RTS,S免疫原性呈正相关。接种疫苗后,针对PfCSP的C末端和NANP重复区域以及PfMSP5和PfMSP1阻断2的IgG水平升高,与6个月内临床疟疾风险较低显著相关。因此,在调整先前的Pf暴露后,免疫启动、抗PfCSP C末端和非靶点抗体反应有助于预防疟疾,这可为优化免疫原和疫苗接种策略提供指导。